XNASTNDM
Market cap2.36bUSD
Jan 10, Last price
36.00USD
1D
-3.97%
1Q
-2.89%
Jan 2017
67.44%
IPO
64.84%
Name
Tandem Diabetes Care Inc
Chart & Performance
Profile
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 747,718 -6.68% | 801,217 14.00% | |||||||
Cost of revenue | 549,695 | 527,345 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 198,023 | 273,872 | |||||||
NOPBT Margin | 26.48% | 34.18% | |||||||
Operating Taxes | 2,357 | 1,742 | |||||||
Tax Rate | 1.19% | 0.64% | |||||||
NOPAT | 195,666 | 272,130 | |||||||
Net income | (222,611) 135.33% | (94,594) -707.70% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,184 | 17,469 | |||||||
BB yield | -0.22% | -0.61% | |||||||
Debt | |||||||||
Debt current | 34,120 | 13,121 | |||||||
Long-term debt | 529,239 | 543,401 | |||||||
Deferred revenue | 13,331 | 16,874 | |||||||
Other long-term liabilities | 31,830 | 23,918 | |||||||
Net debt | 95,447 | (68,679) | |||||||
Cash flow | |||||||||
Cash from operating activities | (31,810) | 50,464 | |||||||
CAPEX | (26,804) | (42,952) | |||||||
Cash from investing activities | (85,740) | 33,168 | |||||||
Cash from financing activities | 4,113 | 16,877 | |||||||
FCF | 172,478 | 155,067 | |||||||
Balance | |||||||||
Cash | 467,912 | 616,901 | |||||||
Long term investments | 8,300 | ||||||||
Excess cash | 430,526 | 585,140 | |||||||
Stockholders' equity | (950,365) | (730,941) | |||||||
Invested Capital | 1,741,885 | 1,631,557 | |||||||
ROIC | 11.60% | 17.75% | |||||||
ROCE | 25.02% | 30.41% | |||||||
EV | |||||||||
Common stock shares outstanding | 64,969 | 64,146 | |||||||
Price | 29.58 -34.19% | 44.95 -70.14% | |||||||
Market cap | 1,921,783 -33.35% | 2,883,363 -70.23% | |||||||
EV | 2,017,230 | 2,814,684 | |||||||
EBITDA | 213,738 | 288,202 | |||||||
EV/EBITDA | 9.44 | 9.77 | |||||||
Interest | 9,882 | 4,313 | |||||||
Interest/NOPBT | 4.99% | 1.57% |